BioTech Nation ... with Dr. Moira Gunn – Détails, épisodes et analyse

Continuous monitoring ... when we want it, when we don’t, should we share it? Or not. Or perhaps just part of it. Dr. Kal Patel, the Co-Founder and CEO of BrightInsight talks about this brave new frontier.

Dr. Chris Gibson, the co-founder and CEO of Recursion Pharmaceuticals in Salt Lake City. We talk about their efforts to map ALL of human biology, and how this mapping will lead to better drugs. 

This week on BioTech Nation, Dr. Sam Blackman, Founder and Head of Research and Development from Day One Biopharmaceuticals, shares the story behind the FDA approval of a groundbreaking drug for the most common childhood brain cancer. He talks about their innovative approach to starting a biopharma company and how it led to a newly FDA approved drug that treats the most common form of brain cancer in children

This week we have a best of rerun with Dr. Mark Sumeray from Amolyt Pharma. Dr. Sumeray talks about their innovative approach to treating hormonal conditions. We’ll talk about two – when your parathyroid has been injured or removed, often during thyroid surgery, and another – when the pituitary starts overproducing growth hormone.

This week Dr. Daniel Kraft, Tech Nation Health Chief Correspondent, discusses advanced health tech. Dr. Kraft highlights his use of wearables like the Apple Watch, Oura ring, and non-invasive blood pressure monitors. He also introduces "otherables," which track health without being worn, using devices like cameras and modified WiFi. These technologies enable continuous health monitoring and personalized care. 

This week on BioTech Nation, Dr. Moira Gunn and Dr. Daniel Kraft discuss how robotics, AI, and virtual reality are transforming surgery. These technologies make procedures less invasive and improve training and outcomes worldwide. Future advancements may include tiny robots performing internal procedures. Security is crucial to prevent hacking of medical devices. 

Dr. John Scarlett, President and CEO of Geron Corporation talks about their drug Imetelstat for myelodysplastic syndrome (MDS). MDS patients often require frequent blood transfusions, impacting their quality of life. Imetelstat, a telomerase inhibitor, aims to reduce transfusion dependence by targeting cancer cells in the bone marrow. Phase three trials showed promising results, with 40% of patients experiencing at least an 8-week transfusion-free interval. 

Dr. Daniel Kraft, Tech Nation Health Chief Correspondent discusses the gap between medical innovation and its adoption into standard practice. He highlights that it typically takes 17 years for a medical discovery to become common practice, but big data and AI could accelerate this. He emphasizes the importance of sharing medical data and initiatives like Stuff That Works Health and EveryCure. 

This week, Dr. Steve Quake from the Chan Zuckerberg Initiative about their goal to tackle all human diseases in the next century. We discuss CZI's innovative approach, including building Biohubs and funding collaborative research. Dr. Quake explains the importance of something called The Virtual Cell project, aiming to use AI to model every human cell. We also address ethical concerns about AI in bioweapons research and the need for regulatory measures. 

This week on Biotech Nation, I speak with Dr. Neal Kassell about focused ultrasound technology. We discuss its noninvasive approach, its diverse applications in treating various medical conditions, and its potential to revolutionize treatments for diseases like Alzheimer's, Parkinson's, and cancer. Dr. Kassell also shares insights into ongoing clinical trials and the rapid growth of focused ultrasound as a global standard of care.